How to reconstitute DSIP: mixing and storage
An experimental sleep peptide with small, mixed human studies and no FDA-approved dose.
Also called: Delta sleep-inducing peptide, Delta-sleep-inducing peptide, Emideltide.
Sleep peptides · Experimental nine-amino-acid peptide with uncertain sleep-signaling targets.
Comes as: Freeze-dried powder vials reported by users, Homemade or premixed nasal sprays reported by users.
Mixed with: Community reports use bacteriostatic water for injections and sterile saline for nasal sprays. Neither is an approved DSIP sleep formulation..
Common vial sizes: 5, 10 mg. Common water amounts: 2, 3, 10 mL.
- Reported examples: 5 mg with 2 mL or 3 mL bacteriostatic water; 10 mg with 10 mL saline for a nasal preparation.
- These are community mixing amounts. They do not establish stability, a sterile process or a validated delivered nasal dose.
- Syringe units measure volume, not peptide mass. Spray output must be measured; it cannot be assumed from bottle volume.
- A trial’s IV diluent or dose does not validate home subcutaneous or nasal preparation.
Before mixing: No validated dry-vial storage schedule was found for the community products described.
After mixing: No verified DSIP-specific after-mixing shelf life was found. A clear solution does not establish sterility or potency.
Related to DSIP
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- CJC-1295 without DAC: A peptide intended to trigger growth hormone release, with no human dosing study found.
- Pinealon: A peptide with unproven brain benefits and no established injection dose.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Download medicine data, European Medicines Agency · European Medicines Agency · 2026
- FDA Briefing Document: Emideltide-Related Bulk Drug Substances (Emideltide (free base) and Emideltide acetate), U.S. Food and Drug Administration · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- Sepsis, NHS · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Anaphylaxis, NHS · NHS · 2023
- Low blood sugar (hypoglycaemia), NHS · 2023
- [Using deltalicin for the treatment of patients with diabetic retinopathy]., Kresiun NV et al. · Eksperimental'naia i klinicheskaia farmakologiia · 2014
- The influence of deltalycyn and transcranial cerebellar stimulation upon recovery of retina after photo stress in patients with diabetic retinopathy., Kresyun NV et al. · Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi · 2014
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.